Open access
Oct 2026
A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): Current and Future Perspectives.
Overall, continuous systemic treatment post-CRT may be key to improving long-term outcomes and represents a mindset shift for both healthcare professionals and patients, which may need to consider unresectable stage III EGFRm NSCLC as a chronic disease, requiring long-term treatment to maintain suppression of disease.
T. Reungwetwattana, Kristin A. Higgins, I. Casarini et al.
· Targeted oncology · 0 citations